BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18171986)

  • 1. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.
    Wu M; Soler DR; Abba MC; Nunez MI; Baer R; Hatzis C; Llombart-Cussac A; Llombart-Bosch A; Aldaz CM
    Mol Cancer Res; 2007 Dec; 5(12):1285-95. PubMed ID: 18171986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
    Jan R; Huang M; Lewis-Wambi J
    Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells.
    Vendrell JA; Ghayad S; Ben-Larbi S; Dumontet C; Mechti N; Cohen PA
    Oncogene; 2007 Jul; 26(32):4656-67. PubMed ID: 17297453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
    Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
    Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
    Ghayad SE; Vendrell JA; Bieche I; Spyratos F; Dumontet C; Treilleux I; Lidereau R; Cohen PA
    J Mol Endocrinol; 2009 Feb; 42(2):87-103. PubMed ID: 18984771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
    Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
    Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
    BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
    Li J; Lu M; Jin J; Lu X; Xu T; Jin S
    Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells.
    Yu T; Cheng H; Ding Z; Wang Z; Zhou L; Zhao P; Tan S; Xu X; Huang X; Liu M; Peng M; Qiu YA
    Mol Cell Endocrinol; 2020 Apr; 506():110762. PubMed ID: 32087276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dependency of Tamoxifen Sensitive and Resistant ER
    Bhasin S; Dusek C; Peacock JW; Cherkasov A; Wang Y; Gleave M; Ong CJ
    Cells; 2023 Jun; 12(13):. PubMed ID: 37443749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.
    Jansen MP; Ruigrok-Ritstier K; Dorssers LC; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Helleman J; Sleijfer S; Klijn JG; Foekens JA; Berns EM
    Breast Cancer Res Treat; 2009 Jul; 116(2):263-71. PubMed ID: 18629630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
    Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
    Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer.
    Chan CM; Lykkesfeldt AE; Parker MG; Dowsett M
    Clin Cancer Res; 1999 Nov; 5(11):3460-7. PubMed ID: 10589759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.
    Zhang Y; Wester L; He J; Geiger T; Moerkens M; Siddappa R; Helmijr JA; Timmermans MM; Look MP; van Deurzen CHM; Martens JWM; Pont C; de Graauw M; Danen EHJ; Berns EMJJ; Meerman JHN; Jansen MPHM; van de Water B
    Oncogene; 2018 Apr; 37(14):1869-1884. PubMed ID: 29353882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.